Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor

American Journal of Cardiovascular Drugs

Volumn 13, Issue 5, 2013, Pages 331-342

  Mendell, Jeanne ^a   Zahir, Hamim ^a   Matsushima, Nobuko ^b   Noveck, Robert ^c   Lee, Frank ^d   Chen, Shuquan ^a   Zhang, George ^a   Shi, Minggao ^a  

^a DAIICHI SANKYO INC   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CELERION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; CARDIOVASCULAR AGENT; DIGOXIN; DRONEDARONE; EDOXABAN; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; VERAPAMIL;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERACTION; DRUG POTENCY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; CARDIOVASCULAR AGENTS; COHORT STUDIES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FACTOR XA; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; PYRIDINES; THIAZOLES; YOUNG ADULT;

EID: 84885129987     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0029-0     Document Type: Article

References (31)

1. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.
2. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012;129(4):e77-82.
3. Lixiana (package insert). Tokyo, Japan: Daiichi Sankyo Co. Ltd.; 2011.
4. Raskob G, Buller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M. The Hokusai VTEi. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost. 2013. doi: 10.1111/jth.12230
5. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next GEneration in atrial fibrillation- thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635-41.
6. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-41.
7. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-53.
8. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250-5.
9. International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
10. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36(2-3):179-94.
11. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927-41.
12. US Food and Drug Administration. Guidance for industry. Drug interaction studies - design, data analysis, implications for dosing, and labeling instructions. 2012. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 20 May 2012.
13. Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T et al. Edoxaban transport via P-glycoprotein is a key factor for the drug disposition. Presented at the 18th North American Regional ISSX Meeting. 14-18 Oct 2012. Available at: http://c.ymcdn.com/sites/issx.site-ym.com/resource/ resmgr/18th-NA-Meeting/Dallas-Online-Abstracts-Book.pdf. 2012 (Abstract P62).
14. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107(5):925-36.
15. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40(1):91-8.
16. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006;26(11):1601-7.
17. Sziraki I, Erdo F, Beery E, Molnar PM, Fazakas C, Wilhelm I, et al. Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen. 2011;16(8):886-94.
18. ® (dronederone) tablets. Full prescribing information. Bridgewater, NJ: sanofi-aventis US, LLC; 2012.
19. ® (amioderone) 400 mg tablets. Full prescribing information. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2010.
20. Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol. 2012;60(4):335-41.
21. Mendell J, Basavapathruni R, Swearingen D, Draves A, Zhang G, Morganroth J. A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor. J Clin Pharmacol. 2011;51(8):1241-6.
22. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(5):687-94.
23. Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost. 2012;108(1):166-75.
24. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006;34(5):786-92.
25. Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos. 2006;34(2):203-7.
26. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000;17(2):209-15.
27. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer. 1995;31A(7-8):1295-8.
28. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013; (in press).
29. ® (dabigatran etexilate mesylate) Full prescribing information. Boehringer Ingelheim Pharmaceuticals Inc.; 2012.
30. ® (rivaroxaban) tablets. Full prescribing information. Titusville, New Jersey: Janssen Pharmaceutical, Inc.; 2011.
31. ® (apixaban) tablets for oral use. Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2012.